Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Multiple Sclerosis

  Free Subscription


14.10.2019

1 Acta Neurol Scand
1 Int J Neurosci
1 J Neuroimmunol
3 J Neurol
1 Mult Scler
3 Neurology
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Neurol Scand

  1. CASTREN E, Heinonen T, Makinen K, Hamalainen P, et al
    The rate of neuropsychological assessments in multiple sclerosis has increased - A retrospective study in a Finnish central hospital.
    Acta Neurol Scand. 2019 Oct 4. doi: 10.1111/ane.13175.
    PubMed     Text format     Abstract available


    Int J Neurosci

  2. TOBORE TO
    Towards a Comprehensive Etiopathogenetic and Pathophysiological Theory of Multiple Sclerosis.
    Int J Neurosci. 2019 Oct 7:1-41. doi: 10.1080/00207454.2019.1677648.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  3. MOHAMMADZADEH A, Rad IA, Ahmadi-Salmasi B
    CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.
    J Neuroimmunol. 2018;323:105-108.
    PubMed     Text format     Abstract available


    J Neurol

  4. MORALES FS, Koralnik IJ, Gautam S, Samaan S, et al
    Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Oct 3. pii: 10.1007/s00415-019-09557.
    PubMed     Text format     Abstract available

  5. ROMEO MAL, Garassino MC, Moiola L, Galli G, et al
    Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    J Neurol. 2019 Oct 4. pii: 10.1007/s00415-019-09562.
    PubMed     Text format    

  6. KAMM CP, Barin L, Gobbi C, Pot C, et al
    Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
    J Neurol. 2019 Oct 8. pii: 10.1007/s00415-019-09563.
    PubMed     Text format     Abstract available


    Mult Scler

  7. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Text format     Abstract available


    Neurology

  8. TUR C, Kalincik T, Oh J, Sormani MP, et al
    Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
    Neurology. 2019 Oct 7. pii: WNL.0000000000008319.
    PubMed     Text format     Abstract available

  9. BERGER JR, Cree BA, Greenberg B, Hemmer B, et al
    Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed     Text format    

  10. LALIVE PH, Roth S, Du Pasquier R
    Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed     Text format    


    PLoS One

  11. JONGEN PJ, van Mastrigt GA, Heerings M, Visser LH, et al
    Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trial.
    PLoS One. 2019;14:e0223482.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: